Epstein-Barr virus (EBV) DNA is found within the malignant cells of some subtypes of lymphoma, and viral presence is being exploited for improved diagnosis, monitoring, and management of affected patients. Recent work suggests that viral genomic polymorphism, such as partial deletion of the viral genome, could interfere with virus detection in tumor tissues. To test for atypical forms of the EBV genome, 98 lymphomas and 6 infected cell lines were studied using a battery of 6 quantitative polymerase chain reaction assays targeting disparate sections of EBV DNA. Fifty of the lymphomas (51%) had no amplifiable EBV DNA, and 38 lymphomas (39%) had low-level EBV infection that was deemed incidental based on EBV-encoded RNA (EBER) in situ hybridization results. The remaining 10 lymphomas (10%) had high EBV loads and EBER localization to malignant cells by EBER in situ hybridization. All 10 represented lymphoma subtypes were previously associated with EBV (Burkitt, diffuse large B-cell, or T-cell type), whereas no remnants of EBV were detected in other lymphoma subtypes (follicular, small lymphocytic, mantle cell, or marginal zone type). Interestingly, 4 of the 10 infected lymphomas had evidence of atypical viral genomes, including 3 of 4 infected T-cell lymphomas with aberrant loss of LMP2 amplicons, and a single diffuse large B-cell lymphoma lacking the central part of the viral genome spanning BamH1W, BZLF1, and EBNA1 gene segments. A reasonable screening strategy for infected malignancy involves applying EBER1 and LMP1 quantitative polymerase chain reaction assays and confirming that values exceeding 2000 copies of EBV per 100,000 cells have EBER localization to malignant cells.
Abstract: Epstein-Barr virus (EBV) DNA is found within the malignant cells of some subtypes of lymphoma, and viral presence is being exploited for improved diagnosis, monitoring, and management of affected patients. Recent work suggests that viral genomic polymorphism, such as partial deletion of the viral genome, could interfere with virus detection in tumor tissues. To test for atypical forms of the EBV genome, 98 lymphomas and 6 infected cell lines were studied using a battery of 6 quantitative polymerase chain reaction assays targeting disparate sections of EBV DNA. Fifty of the lymphomas (51%) had no amplifiable EBV DNA, and 38 lymphomas (39%) had low-level EBV infection that was deemed incidental based on EBV-encoded RNA (EBER) in situ hybridization results. The remaining 10 lymphomas (10%) had high EBV loads and EBER localization to malignant cells by EBER in situ hybridization. All 10 represented lymphoma subtypes were previously associated with EBV (Burkitt, diffuse large B-cell, or T-cell type), whereas no remnants of EBV were detected in other lymphoma subtypes (follicular, small lymphocytic, mantle cell, or marginal zone type). Interestingly, 4 of the 10 infected lymphomas had evidence of atypical viral genomes, including 3 of 4 infected T-cell lymphomas with aberrant loss of LMP2 amplicons, and a single diffuse large B-cell lymphoma lacking the central part of the viral genome spanning BamH1W, BZLF1, and EBNA1 gene segments. A reasonable screening strategy for infected malignancy involves applying EBER1 and LMP1 quantitative polymerase chain reaction assays and confirming that values exceeding 2000 copies of EBV per 100,000 cells have EBER localization to malignant cells. E pstein-Barr virus (EBV) is present within the malignant lymphocytes of most endemic Burkitt lymphomas, nasal T/natural killer lymphomas, and lymphomas arising in patients with primary or iatrogenic immune deficiencies and is also associated with a subset of sporadic B-cell and T-cell lymphomas. 1 The laboratory assay typically used to classify a tumor as being EBVrelated is EBV-encoded RNA (EBER) in situ hybridization, as EBER is expressed in latently infected cells, and this assay can localize the infection to the malignant cell population. 1 Immunohistochemical stains are used to localize expressed viral proteins to tumor cells, but the spectrum of viral protein expression differs among tumor types, and so, there is concern for false-negative test results. A tumor clone harboring a partially deleted EBV genome could go undetected by expression-based assays if the loss of genetic material results in atypical patterns of EBV gene expression.
Partially deleted or rearranged EBV DNA has been identified in some EBER-negative sporadic Burkitt lymphomas, which suggests that EBV DNA (or remnants of the EBV genome) may be present in a greater proportion of lymphomas than previously assumed. 2, 3 Prior molecular characterization of infected lymphomas identified 2 AIDS-related lymphomas with false-negative tests for selected segments of the EBV genome, one of which had selective deletion of LMP2 gene sequences and another with selective dropout of BZLF1 and LMP1 amplicons. 4 Molecular characterization of infected gastric adenocarcinomas revealed an infected tumor with amplifiable LMP1 but lacking 5 other segments of the viral genome that were queried by quantitative polymerase chain reaction (Q-PCR). 5 These examples suggest that tumors with atypical viral genomes may elude detection by commonly used laboratory assays and raise the question of whether remnants of the viral genome are present in tumor subtypes that have not previously been associated with viral infection.
Beyond the potential for interference with laboratory tests, viral gene polymorphism could impact viral pathogenicity. Variants in the EBV genes LMP1, EBNA2, EBERs, and BARF1 are reportedly more common in infected tumors than in geographically matched nontumor control subjects. [6] [7] [8] [9] [10] [11] [12] Research into the clinicopathologic significance of these polymorphisms is facilitated by cataloging viral genomic variants in public databases such as the Virus Pathogen Resource at http://www.viprbrc.org.
In the current study, we used a battery of real-time Q-PCR assays to amplify 6 disparate segments of the EBV genome (LMP2, EBER1, BamH1W, BZLF1, EB-NA1, and LMP1) in non-Hodgkin lymphomas of varying histologic subtypes. Tumors with measurable viral loads or EBER localization to malignant cells by in situ hybridization were further studied using a panel of immunohistochemical stains to characterize LMP1 expression (associated with latent EBV infection) and BZLF1 and BMRF1 expression (associated with lytic EBV infection). Our goal was to evaluate a wide range of lymphoma subtypes for evidence of segmental viral genomic deletion, which has implications for etiologic mechanisms of viral oncogenesis and for design of laboratory tests to diagnose, monitor, and treat patients with EBV-infected tumors.
METHODS

Study Samples
Archival paraffin-embedded tumor tissue from 107 patients was retrieved from the clinical files of hospitals affiliated with the University of North Carolina and the University of Vermont. Tumors were selected to represent a spectrum of non-Hodgkin lymphoma subtypes, including lymphomas commonly associated with EBV (peripheral T-cell lymphoma, diffuse large B-cell lymphoma, and Burkitt lymphoma) as well as subtypes not usually associated with EBV [follicular lymphoma, marginal zone lymphoma including mucosa-associated lymphoid tumor (MALT), mantle cell lymphoma, and small lymphocytic lymphoma]. Experienced hemtopathologists (C.H.D., R.J.B., and Y.F.) confirmed that tumor was present in each sample and corroborated the histologic subtype using World Health Organization criteria. 13 This study was done with approval of the Institutional Review Board.
Quantitative Real-Time PCR
Q-PCR assays targeted and quantified 6 disparate regions of the EBV genome ( Fig. 1 ) in DNA extracted from two 10-mm-thick paraffin sections cut from archival blocks, as previously described. 4,5 All 6 Q-PCRs (for BamH1W, EBNA1, LMP1, LMP2, EBER1, and BZLF1 segments) were previously validated on dilutions of cell line DNA and on paraffin-embedded malignant tissues of known EBV status. 4, 5 One lymphoma with evidence of selective dropout of BamH1W amplicons was subjected to an alternate Q-PCR assay for the BamH1W region developed by Lo et al. 14 The alternate Q-PCR assay was validated by showing that viral loads measured using the alternate assay were equivalent to viral loads measured using our primary BamH1W Q-PCR assay when both assays were applied to 5 EBER-positive and 5 EBERnegative lymphomas.
For all 6 Q-PCRs, BLAST sequence analysis indicated no significant primer or probe homology with human DNA or other herpesvirus genomes. Cross-reactivity with other herpesviruses was further examined by running each Q-PCR on purified cytomegalovirus (CMV), HHV8 (Kaposi sarcoma-associated herpesvirus), varicella zoster virus (VZV), and herpes simplex virus (HSV-1) DNA; formalin-fixed paraffin-embedded tissue from 5 patients diagnosed with other herpes family viruses (3 with CMV, 2 with herpes simplex); and a paraffin-embedded pellet of the EBV-negative BL30 human lymphoma cell line.
PCR and product detection was performed on an ABI Prism 7500 Real-Time PCR instrument with Sequence Detection System software (Applied Biosystems, Foster City, CA). Thermocycling conditions were: 501C for 2 minutes and 951C for 10 minutes, followed by 40 cycles at 951C for 15 seconds and 601C for 1 minute. Each 25 uL reaction contained 1X TaqMan Universal Master Mix, TaqMan probe (10 pmoL), and 1 uL of DNA template. Assays targeting LMP1 and BZLF1 used 30 pmoL of forward and reverse primers, whereas all other assays used 15 pmoL of each primer. Standard curves were generated for each assay using serial 10-fold dilutions of Namalwa Burkitt lymphoma DNA (cell line from American Type Culture Collection, Rockville, MD) having 2 copies of the EBV genome 15 and 2 copies of the APOB human control gene per cell. Standard curves were deemed acceptable if they demonstrated analytic sensitivity to 50 or fewer copies of EBV DNA, a difference of 3.3 ± 0.3 cycles between 10-fold dilutions, and a correlation coefficient of at least 0.99. Q-PCR of a segment of the human APOB gene was used to confirm the efficacy of DNA extraction and to calculate the number of cells amplified per reaction. Samples with fewer than 40 cells (as measured by Q-PCR targeting human APOB against a Namalwa cell line standard) were retested for APOB and for all 6 EBV DNA targets at higher or lower template volumes, and samples with consistently low APOB levels were excluded from further analysis. To check for amplicon contamination, every run contained at least 2 "no template" controls in which nuclease-free H 2 O was substituted for template. All experimental samples were run in duplicate, and mean viral loads were calculated based on the ratio of EBV to APOB copies in a given volume of extracted DNA, expressed as the number EBV DNA copies per 100,000 cells. Samples with no measurable EBV DNA were reported as having viral loads of 0.
Paraffin-embedded Cell Lines
Well-described EBV-infected cell lines were fixed, embedded in paraffin, and tested by the battery of 6 EBV Q-PCRs. The B95-8 lymphoblastoid cell line is reported to harbor both episomal and replicative EBV genomes. 16 Chromosomal integration of the viral genome in Namalwa Burkitt lymphoma, BL30-B95-8 superinfected Burkitt lymphoma, and IB4 lymphoblastoid B-cell lines affects the terminal repeat structure [17] [18] [19] that could disrupt LMP2 reading frames, possibly interfering with intracellular signaling and lytic viral replication. Raji Burkitt lymphoma cells are reported to harbor a mixture of episomal and integrated genomes, with integration affecting the structure of the BamH1W-Y region. 20 The BL30-P3HR1 superinfected Burkitt line harbors the P3HR1 strain of EBV, which has multiple genomic variations (eg, deletions, mutations) compared with the prototypic B95-8 strain. 21, 22 Each cell line was grown in standard culture conditions, and cell pellets were fixed in 10% buffered formalin and then suspended in low-melting temperature agarose or fibrin clots before embedding in paraffin. Total DNA was extracted from paraffin sections, and EBV DNA was amplified by the same methods used for patient samples. The Namalwa cells that were paraffin embedded had been serially passaged for several years, whereas fresh Namalwa cell line DNA was used for assay calibration. To verify the linearity and sensitivity of each Q-PCR assay, we performed Q-PCR on serial 10-fold dilutions of template DNA extracted from paraffin-embedded Namalwa and Raji cell line samples with known EBV copy numbers (2 copies and about 55 copies of EBV DNA per cell, respectively). 15, 20, 23, 24 EBER In Situ Hybridization Each tumor was assayed for latent EBV infection by EBER in situ hybridization performed on an automated system that utilized fluorescein-labeled EBER probe and colorimetric detection (Ventana Benchmark; Ventana Medical Systems, Tucson, AZ). A parallel hybridization using oligo(d)T probe served as a control for RNA preservation. A molecular hematopathologist (M.L.G.) classified tumors as EBER-positive if the EBER signal was localized to malignant appearing cells, or as EBERnegative if the signal was undetectable or was localized only to benign cells.
Immunohistochemistry for Viral LMP1, BMRF1, and BZLF1 Proteins
Immunohistochemical assays to detect expression of selected viral proteins were performed on paraffin sections of all lymphoma tissues that were EBER-positive or had measurable EBV DNA by any of the 6 Q-PCR assays. EBV LMP1 staining was done as previously described 4 using citrate retrieval and the anti-EBV LMP1-clone CS1-4 cocktail of mouse monoclonal antibodies (1:100; Dako, Carpinteria, CA). Immunohistochemical detection of the EBV replicative proteins BMRF1 and BZLF1 was performed using citrate retrieval and anti-BMRF1 clone G3-E31 (1:200 dilution; Research Diagnostics Inc., Flanders, NJ) or anti-BZLF1 clone BZ.1 (1:25 dilution; Dako), with primary antibody treatment for 30 minutes at 371C. The Super-Sensitive Non Biotin HRP Detection Kit with diaminobenzidine chromogen (Biogenex, San Ramon, CA) was used for blocking and detection. Tissues were counter stained with hematoxylin (Dako, Glostrup, Denmark) and interpreted for signal localization to tumor cells. Positive controls were a known EBV-related Hodgkin lymphoma (for LMP1) and an oral hairy leukoplakia (for BMRF1 and BZLF1).
Statistical Analyses
Means and SDs were compared with determine concordance of viral load measurements across the 6 Q-PCR assays, and to identify atypical EBV-positive cases as assessed by evidence of selective failure of 1 or more Q-PCR assays in a given case. We used receiveroperating characteristic analyses 25 to evaluate Q-PCR viral load threshold as a method for distinguishing between tumors with neoplastic versus non-neoplastic (incidental) EBV infection (as defined by the gold standard EBER in situ hybridization). This was accomplished by plotting the true-positive rate against the false-positive rate when various viral load thresholds were applied, and calculated area under the curve (AUC) was used to estimate the proportion of paired neoplastic and non-neoplastic samples that would be classified correctly for each viral load threshold. All P-values reported for statistical tests of differences in means and proportions are 2-sided.
RESULTS
EBV DNA Measurements by Q-PCR in Infected or Uninfected Lymphoid Cell Lines
EBV copy numbers in serially diluted paraffin-embedded Namalwa and Raji cell lines demonstrated that all 6 Q-PCR assays were sensitive to fewer than 50 copies per PCR and were linear over at least 3 orders of magnitude. No amplification was seen when pure viral DNA samples of CMV, HHV8, VZV, or HSV-1 were used as the template for Q-PCR assays ( Table 1) . Amplification was also negative in the EBER-negative BL30 human cell line and the 2 HSV-positive patient samples. All 3 CMV-related colon lesions had low levels of EBV DNA detected by at least 2 independent Q-PCR assays, but no amplification was observed with purified CMV DNA; therefore, we concluded that the weak EBV signal in the CMV-positive biopsies reflected true EBV DNA presence, which is not unexpected in human tissue samples given the ubiquitous prevalence of EBV infection in adults. In total, these findings suggest no cross-reactivity of the 6 EBV Q-PCR assays with any of the other herpesvirus family members tested.
If each infected cell line contains only intact EBV genomes (without segmental deletions or gene amplifications), we would expect comparable viral load estimates across all of the Q-PCR assays except the assay for BamH1W, a known repeat sequence. 4,5 However, we observed some discrepancies among the 6 viral loads in most cell lines ( Table 2 ). In 4 of the cell lines (Namalwa, Raji, B95-8, and BL30-B95-8), there was a >9-fold difference between the lowest and highest viral load estimate (eg, ranging from 112 copies of LMP2 to 1265 copies of LMP1 DNA in the BL30-B95-8 cell line), whereas there was less than a 5-fold difference in viral loads for the 2 remaining cell lines (IB4 and BL30-P3HR1, with viral loads ranging from 1 to 3 and 2 to 9 copies per cell, respectively). A noticeable trend is that LMP2 values copy numbers were relatively low compared with copy numbers of the other EBV gene segments, which could indicate a problem with assay calibration or assay efficiency for the LMP2 gene segment. Alternatively, it could indicate that the LMP2 segment was consistently defective (eg, deleted or mutated) in a way that interfered with its enumeration in each cell line, but this explanation seems less plausible because LMP2 copy numbers were also relatively low in the naturally infected lymphomas as described below.
The Namalwa cell line is reported to have 2 integrated copies of the EBV genome per cell. 15 We confirmed 2 copies (± 1 copy) per cell in paraffin-embedded samples of Namalwa cells based on LMP2, EBER1, BZLF1, EBNA1, and LMP1 assays ( Table 2 ). In contrast, we measured 24 copies per cell of the BamH1W segment, a tandem repeat sequence with varying copy numbers across strains of EBV. Copy numbers of tandem repeat segments have been reported to fluctuate during longterm cell culture and during lytic viral replication. 26 When the BamH1W and LMP2 regions are excluded from consideration, copy numbers based on the remaining 4 
Q-PCR and EBER In Situ Hybridization Results in Patient Samples
Nine patient tumors were excluded from further analyses because of inadequate tissue (5 MALT lymphomas), inadequate APOB amplification (2 diffuse large B-cell lymphomas), or missing histologic subtype data (2 tissues), leaving 98 unique archival paraffin-embedded human lymphoma samples that were evaluable by Q-PCR, EBER in situ hybridization, and at least 2 immunohistochemical assays (Table 3) .
PCR assays were negative for all 6 EBV segments in 50 samples and positive for at least 1 EBV segment in 48 samples. Mean estimated APOB copy numbers were comparable between PCR-negative and PCR-positive cases [PCR negative: 8105 copies/PCR; 95% confidence interval (CI), 5363-10,847 and PCR positive: 7223 copies/ PCR; 95% CI, 4700-9746; P = 0.6]. All 50 PCR-negative samples were also EBER in situ hybridization negative.
Thirty-eight PCR-positive tumors were classified as non-neoplastic (incidental) EBV infections based on lack of localization to malignant cells by EBER in situ hybridization (Table 3 ). Only 3 of these tumors had amplification of all 6 EBV segments (Table 4 ). BamH1W was the most common target amplified from these samples (n = 30/38 tissues positive), with a mean copy number of 119 EBV copies/100,000 cells (range, 1 to 870). PCRpositive/EBER-negative samples were identified among all histologic subtypes but were most common among the marginal zone lymphomas (10 of 15 samples, including 9 of the 14 subclassified as MALT) and mantle cell lymphomas (2 of 3 samples).
The 10 remaining PCR-positive samples were classified as neoplastic EBV infections based on EBER localization to malignant cells by in situ hybridization (4 Burkitt, 3 diffuse large B-cell, and 3 T-cell lymphomas). Six of these PCR-positive/EBER-positive samples had high copy numbers for all EBV target segments and were classified as "typical" neoplastic infections ( Table 5 ). The remaining 4 were classified as "atypical" infections because at least 1 EBV segment failed to amplify or was amplified at a relatively low level (at least 10-fold lower than the next highest value). These included 1 diffuse large B-cell lymphoma with virtually no amplification of BamH1W, BZLF1, or EBNA1, and 3 T-cell lymphomas with little or no amplification for LMP2. All 4 atypical samples amplified LMP1 and EBER1 (the latter in keeping with positive EBER in situ hybridization results). Mean copy numbers were lower for EBV targets amplified from atypical versus typical EBV-positive lymphomas but were nonetheless 27 to 223 times higher than corresponding mean copy numbers for EBV targets amplified in PCR-positive/EBER-negative samples.
EBV Protein Expression
Immunohistochemical assays aimed at localizing lytic (BZLF1 and BMRF1) or latent (LMP1) EBV infection to neoplastic cells were negative in all 43 PCRpositive/EBER-negative samples tested. Five additional samples could not be assayed for LMP1 protein because tissue had been exhausted.
Among the 10 EBER-positive tumors ( Table 5) , immunohistochemistry results varied. Two of 6 samples classified as typical infections expressed both BZLF1 (a sign of early lytic viral replication) and BMRF1 (a sign of active lytic replication), whereas another expressed only BZLF1, and none expressed LMP1. Two of 4 samples classified as atypical EBV infections expressed all 3 viral proteins (LMP1, BZLF1, and BMRF1). BZLF1 protein expression was negative in the atypical sample having evidence of BZLF1 amplicon dropout, but this is not necessarily attributable to gene deletion as staining was also negative in 4 samples with high levels of BZLF1 DNA. In all samples with visible EBV protein expression, expression was limited to a small proportion of neoplastic cells. In contrast, EBER was expressed in virtually all malignant cells. 
Q-PCR Can Identify Neoplastic EBV Infections
Receiver-operating characteristic analyses were performed on Q-PCR data from 10 PCR-positive/EBERpositive and 38 PCR-positive/EBER-negative lymphomas to identify the viral load threshold that best distinguished neoplastic EBV infection from incidental EBV infection (Table 6 ). Neoplastic infection was identified with 100% sensitivity when 500 or more copies of EBER1 or LMP1 segments were amplified, whereas sensitivity at this copy number threshold was only 90% for BamH1W, BZLF1, and EBNA1 segments and only 80% for LMP2. These results reflect the low or negative amplification of certain EBV targets in atypical EBER-positive tumors (case #2681 with fewer than 500 copies of BamH1W, EBNA1, and BZLF1, and cases #2778 and #2783 with fewer than 500 copies of LMP2). However, the 500 copy number threshold was sufficient to identify neoplastic (EBERpositive) infections for all 6 EBV genomic targets when *EBER in situ hybridization was negative or localized to non-neoplastic cells only. All tested samples were negative for BZLF1, BMRF1, and LMP1 protein expression in neoplastic cells unless noted.
wInadequate tissue for LMP1 immunohistochemistry. False-positive classification rates decreased as the copy number threshold was increased, so that all incidentally infected cases were classified correctly when a 2000 minimum copy number threshold was applied ( Table 6 ). All neoplastic and incidentally infected cases were correctly classified using a 2000 copy number threshold for EBER1 or LMP1. Because of the atypical infection cases, only 95% of cases were correctly classified (AUC 95% CI, 85%-100%) using a 2000 copy number threshold for BamH1W, BZLF1, or EBNA1, and 85% of cases were correctly classified (AUC 95% CI, 70%-100%) for LMP2. Overall these data suggest that use of EBER1 or LMP1 Q-PCR assays exceeding a threshold of 2000 copies per 100,000 cells would be a reasonable strategy to screen lymphomas for neoplastic EBV infection.
Clinical Characteristics
Age at diagnosis was available for 91 cases and sex was known for 93 cases. Age was similar for patients with PCR-positive and PCR-negative lymphomas (57 y; 95% CI, 51-63 vs. 52 y, 95% CI, 46-58; P = 0.2) but was lower for patients with PCR-positive/EBER-positive lymphomas than PCR-positive/EBER-negative tumors (46 y; 95% CI, 33-60 vs. 59 y; 95% CI, 52-66; P = 0.08). Clear sex differences were not apparent, but patients with PCRpositive lymphomas were somewhat more likely to be male than patients with PCR-negative tumors (74% vs. 64%; P = 0.3) and patients with PCR-positive/EBERpositive tumors were more likely to be male than those with PCR-positive/EBER-negative tumors (80% vs. 72%; P = 0.6). Pathology reports suggested that 4 cases were in immunocompromised patients, including 2 PCR-negative Burkitt lymphomas, 1 PCR-positive/EBER-negative diffuse large B-cell lymphoma, and 1 PCR-positive/EBERpositive Burkitt lymphoma classified as a typical neoplastic infection. Clinical characteristics should be interpreted with caution given that our study included a small convenience sample of cases.
Case Report of an Atypical EBV-infected Lymphoma
One atypical EBER-positive lymphoma (case #2681 in Table 5 ) had little or no amplification of BamH1W, EBNA1, and BZLF1, but relatively high levels LMP2, EBER1, and LMP1 (1745, 13,908 and 92,558 copies per 100,000 cells). These findings are consistent with deletion of the middle section of the viral genome with retention of both ends. All Q-PCR assays were repeated at least 4 times to confirm the viral loads for this tumor. Negative results for the BamH1W segment were confirmed using both primer/probe sets targeting the BamH1W portion of the EBV genome.
This tumor was a diffuse large B-cell lymphoma arising in a 53-year-old Hispanic female. The patient presented with a 3-month history of sore throat, bilateral parotid swelling, and cervical lymphadenopathy. She underwent bilateral tonsillectomy to relieve partial tracheal obstruction. Histologic examination of tonsil tissue revealed sheets of large cells with folded or cleaved nuclei and vesicular chromatin (centroblastic polymorphous appearance). Immunohistochemistry showed expression of CD45 (weak), CD20, CDw75, CD79a, BCL6, and BCL2. The large cells did not express CD10, MUM1, CD138, CD23, TdT, or CD34. CD5 and CD3 stained similar numbers of scattered small benign-appearing lymphocytes. By flow cytometry, the large cells expressed CD71 with dim CD45 and coexpression of CD20 and CD19 with no associated light chain expression or expression of CD10 or CD23. Karyotype showed t(14;18) IGH/BCL2 in addition to complex chromosomal abnormalities: 46X,der(X)t(x;1)(p11.2;q25),t(1;3)(q?24;q27),add (2)(p21),t(14;18)(q32;q21),der(18)t(14;18)(q32;q21) [20] /47, idem,+21 [5] . The tumor was subclassified as a malignant lymphoma, diffuse large B-cell type, germinal center subtype (follicle center cell origin). Human immunodeficiency wAny one of the 6 EBV target segments above the threshold. AUC indicates area under the curve, which represents the probability that the threshold specified will correctly distinguish a random pair of EBER-positive and EBERnegative cases as neoplastic and non-neoplastic, respectively. 95% CI, 95% confidence interval for the AUC.
virus serology was negative. The patient responded well to 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus rituximab followed by involved field radiation to the head and neck. The clinicopathologic findings in this case are not unusual for a lymphoma of this subtype, except for the atypical EBV genomic structure.
DISCUSSION
This study is the first to test for multiple segments of EBV DNA in a wide spectrum of non-Hodgkin lymphoma tissues. EBV was detected only in lymphoma subtypes that are already known to be EBV-related (Burkitt, diffuse large B cell, and T cell), and there was no evidence of EBV DNA remnants in other lymphoma subtypes (follicular, marginal zone, small lymphocytic, and mantle cell). High EBV DNA copy numbers were found only in lymphomas classified as neoplastic EBV infections based on standard EBER in situ hybridization. Correlation between viral load and EBER localization supports the efficacy of quantitative (as opposed to qualitative) DNA amplification as a screening test for EBV-related malignancy. Occasional false-negative Q-PCR results reinforce the utility of EBER in situ hybridization as the gold standard assay for detecting tumor-associated EBV and for defining a tumor as EBV-related.
Low-level EBV DNA (based on Q-PCR amplification of 1 or more EBV targets) was found in some lymphoma tissues despite the absence of latent (EBER, LMP1) or lytic (BZLF1 or BMRF1) viral gene expression, consistent with incidental infection of rare benign lymphoid cells. Interestingly, 4 EBER-positive tumors had evidence of selective dropout of portions of the EBV genome, suggesting genomic deletion or mutation involving BamH1W, EBNA1, BZLF1, or LMP2 gene segments. One of the 4 was a diffuse large B-cell lymphoma with almost complete loss of amplicons in the central portion of the EBV genome (BamH1W, EBNA1, and BZLF1). The remaining 3 cases were T-cell lymphomas with marked, selective reduction of LMP2 amplicons, implying that LMP2 gene defects may be common in infected T-cell tumors.
In prior studies, selective loss of BZLF1, LMP1, or LMP2 amplicons was identified in a fraction of AIDS lymphomas, 4 and selective loss of LMP2 was found in a gastric adenocarcinoma. 4, 5 Another unusual gastric adenocarcinoma had loss of all but the LMP1 amplicon, but it was not possible to determine whether this tumor contained only a small segment of the EBV genome or whether the LMP1 amplification was false positive. 5 If the EBER1 segment of the viral genome can be lost, then previous findings, [2] [3] [4] [5] reinforced by data from the present study, suggest that there is not a single Q-PCR that is completely reliable for detecting tumor-associated EBV infection. This work has implications for the design of assays to identify EBV-associated malignancy. Specifically, it suggests that several disparate EBV gene seg-ments should be assayed by Q-PCR or that the gold standard EBER in situ hybridization assay should be used to maximize the detection of EBV in all types of malignancy.
Identifying EBV is important from a clinical standpoint, as patients with EBV-infected lymphomas may be candidates for novel or alternative therapies targeting virally infected cells. [27] [28] [29] [30] [31] [32] [33] Indeed, progress has been made in treating EBV-related malignancies by infusing EBV-specific cytotoxic T cells, by inducing lytic viral replication, and/or by delivering drugs that leverage virus-driven biochemical pathways.
In clinical settings, Q-PCR of blood or plasma is frequently used to monitor tumor burden in allogeneic transplant recipients or nasopharyngeal carcinoma patients. 1, 34 The high levels of circulating EBV DNA in affected patients presumably derive from death of infected tumor cells. 35 Evidence that selected Q-PCR amplicons may be lost in primary tumor tissue implies that tumorderived viral DNA in body fluids may also fail to amplify, potentially adversely impacting the efficacy of viral load assays in clinical settings. Consequently, it would be prudent to confirm amplification of EBV DNA in tumor tissue or in body fluid at the time of initial diagnosis before using the same assay to amplify EBV DNA in subsequent body fluid specimens as a marker of tumor burden.
Identifying and studying lymphomas with viral genomic deletion or mutation is relevant to understanding oncogenesis, as a corrupted viral coding sequence could result in abnormal viral gene expression affecting the tumorigenic potential of the viral strain. One remarkable case of diffuse large B-cell lymphoma (case #2681 in this study) had evidence suggesting deletion of a large segment of the EBV genome. Assuming the deletion was contiguous across the 3 relevant segments, viral DNA spanning multiple latent and lytic genes as well as microRNA coding sequences would have been lost, resulting in altered transcriptional regulation of both viral and cellular genes. If true, the result implies that these EBV genome segments are not necessary to maintain EBV in lymphoma cells. EBV persistence in the absence of EBNA1, a gene believed to be required for propagation of EBV DNA to daughter cells upon cell division, 36 suggests that episomal partitioning during mitosis may be obviated, which in turn suggests that the residual viral genome is integrated into host chromosomal DNA.
We used the Namalwa cell line as a standard for Q-PCR because it has 2 integrated copies of the EBV genome per cell. When our battery of Q-PCR assays was used to measure viral genome copy number in a later passage of Namalwa cells and in 5 other well-characterized cell lines, certain parts of each viral genome had varying copy numbers that may have resulted from genetic polymorphism (mutation, deletion, gene amplification, or integration into the human genome). Altered copy number of tandem repeat sequences is a well-described phenomenon, and it has been reported that numbers BamH1W repeat sequences can vary during long-term culture and during viral replication. 26 With the exception of the BamH1W repeat region, the remaining segments of the Namalwa genome varied no more than 2-fold (1 PCR cycle) from the expected value, which supports the suitability of Namalwa as a standard for quantifying viral load. Similarly, the IB4 cell line, known to have 2 integrated copies of the EBV genome, had 6 different viral loads varying no more than 2-fold (1 PCR cycle) from the expected value. Given that these cell lines were fixed and paraffin embedded before DNA extraction, the fairly consistent viral loads measured in Namalwa and IB4 support the accuracy of EBV viral load measurements by Q-PCR in fixed tumor tissues.
The Raji Burkitt lymphoma cell line had widely varying viral loads ranging from 2 to 74 copies per cell depending on which genomic segment was targeted by our battery of 6 Q-PCRs. Prior work has identified both episomal and integrated EBV genomes in Raji cells and 4 recurrent integration sites. 37 The relatively low BamH1W copy number measured in Raji cells in the present study could reflect viral genome disruption at the sites of chromosome integration previously described by Gao et al. 37 The B95-8 cell line is a lymphoblastoid cell line that contains the prototypic wild-type EBV genome and demonstrates active lytic viral replication in a subset of infected cells. Our battery of 6 Q-PCRs demonstrated consistent viral loads (within 1 log) and an average viral load of 50 copies per cell. In the BL30-B95-8 cell line, a Burkitt lymphoma line (BL30) superinfected with EBV B95-8 virions, our battery of Q-PCRs demonstrated consistent viral loads (within 1 log), and an average load of 539 copies per cell. This high load (compared with an average of 5 copies per cell in the prototypic B95-8 cell line from which the virus is derived) implies that viral load is not determined by the strain of EBV exclusively. The host cell is not either the only factor influencing viral load, given that the BL30 P3HR1 line derived from the same BL30 parental line yielded much lower viral loads (average 5 copies per cell).
Our Q-PCR assays may be useful to epidemiologists seeking cost-efficient and reliable methods of detecting EBV-related tumors in large numbers of archival paraffinembedded patient samples. Our current data suggest that a viral load of >2000 LMP1 or EBER1 copies per 100,000 cells may be sufficient to identify neoplastic infections with 100% sensitivity and specificity. However, prior work has shown assay interference for LMP1 or EBER1 amplification by virtue of viral genomic mutation or deletion. 4,5 Therefore 2 or more segments of the viral genome should be amplified to reduce the likelihood of a false-negative result. When testing for low-level EBV infection (such as minimal residual disease after therapy), BamH1W seems to be the most sensitive of the Q-PCR assays, 1, 4, 5 probably because it targets a reiterated sequence. The presence of at least 2000 copies of any EBV DNA segment is a reasonable surrogate for infected neoplasia, but confirmatory testing by EBER in situ hybridization is necessary to demonstrate EBV localization to the lesion of interest. Histochemical assays for BZLF1, BMRF1, or LMP1 protein expression do not seem to add value as part of a screening strategy for neoplastic infections, but they may be useful for cancer diagnosis and classification. 1 In conclusion, we have shown that a battery of Q-PCR assays is sensitive and specific for detecting tumor-associated EBV in archival paraffin-embedded patient samples. Our findings suggest that a threshold of 2000 EBV copies per 100,000 cells can be used to distinguish tumors with neoplastic versus incidental EBV infection. Evidence of viral genome variation (such as point mutation, deletion, or chromosomal integration) in a subset of cases is relevant to laboratory medicine practice and has implications for disease pathogenesis. Atypical viral genome structure could interfere with certain assays aimed at viral detection, emphasizing the need to target >1 viral genome segment to maximize identification of infected tumors. Importantly, we did not identify any viral genomic alteration that would have rendered a tumor-specific infection undetectable by EBER in situ hybridization, which reinforces the role of EBER in situ hybridization as the gold standard assay for defining EBV-related malignancy. Our study showed that among EBER-negative tumors, there is scant evidence to support a hit-and-run hypothesis whereby the virus was present during lymphomagenesis but then was partially eliminated, thus retaining only remnants of the viral genome in malignant cells. Further work is needed to precisely characterize viral genomic variants as facilitated by emerging next generation sequencing strategies. Results should be correlated with clinicopathologic findings to shed light on the oncogenic impact of atypical viral genomes.
